Raleigh Capital Management’s ResMed RMD Stock Holding History

Raleigh Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.53K	Sell	13 -32	-71%	-$6.63K	﹤0.01%	424
2026 Q1	$10.1K	Buy	45 +6	+15%	+$1.5K	﹤0.01%	396
2025 Q4	$9.43K	Sell	39 -4	-9%	-$1.02K	﹤0.01%	394
2025 Q3	$11.8K	Sell	43 -8	-16%	-$2.19K	﹤0.01%	357
2025 Q2	$13.2K	Buy	51 +3	+6%	+$716	0.01%	355
2025 Q1	$10.8K	Sell	48 -85	-64%	-$19.8K	﹤0.01%	356
2024 Q4	$30.4K	Sell	133 -19	-13%	-$4.58K	0.01%	387
2024 Q3	$37.1K	Buy	152 +19	+14%	+$4.25K	0.01%	356
2024 Q2	$25.5K	Buy	133 +32	+32%	+$6.49K	0.01%	395
2024 Q1	$20K	Sell	101 -74	-42%	-$13.6K	0.01%	423
2023 Q4	$30.2K	Buy	175 +3	+2%	+$461	0.01%	358
2023 Q3	$25.5K	Buy	172 +28	+19%	+$5.06K	0.01%	359
2023 Q2	$31.5K	Buy	+144	New	+$32.1K	0.02%	300

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raleigh Capital Management's RMD Position: Q2 2026 in Review

Raleigh Capital Management reduced its ResMed (RMD) stake by 71% in Q2 2026, selling an estimated $6.63K and leaving 13 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Raleigh Capital Management first reported a position in RMD in Q2 2023 and has held it in 13 quarters since. The position peaked at $37.1K in Q3 2024. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Raleigh Capital Management held 13 shares of ResMed worth $2.53K as of Q2 2026.
Raleigh Capital Management sold 32 ResMed shares in Q2 2026, an estimated $6.63K.
ResMed made up ﹤0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #424 holding.
Raleigh Capital Management first reported a position in ResMed in Q2 2023 and has held it in 13 quarters since.
Raleigh Capital Management's ResMed position peaked at $37.1K in Q3 2024.
880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.